APAC Childhood Obesity Treatment Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$310.6 MnPlaceholder estimate
Estimate 2025$364.9 Mn20.9% of the global market
Projected 2034$1.56 Bn 326.9%Adds $1.19 Bn over 9 forecast years
CAGR 2025–203417.5%Faster than 79% of 183 Pharmaceuticals markets here
Key players5
APAC is 20.86% of the global market.
Among regions, the largest is North America at $971.9 Mn.
Fastest growing: APAC (this report) at 17.5% a year.
APAC ranks 2nd of 6 by size among regions.
Market size projection
APAC
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$1.19 Bn total, 2026–2034
Year-by-year market size, 2024–2034
Childhood Obesity Treatment Market market size by year, APAC
Year
Market size
Change that year
Since 2025
2024 (estimate)
$310.6 Mn
—
—
2025 (base)
$364.9 Mn
+$54.3 Mn
—
2026 (forecast)
$428.8 Mn
+$63.9 Mn
+17.5%
2027 (forecast)
$503.8 Mn
+$75.0 Mn
+38.1%
2028 (forecast)
$592.0 Mn
+$88.2 Mn
+62.2%
2029 (forecast)
$695.5 Mn
+$103.6 Mn
+90.6%
2030 (forecast)
$817.3 Mn
+$121.7 Mn
+124%
2031 (forecast)
$960.3 Mn
+$143.0 Mn
+163.2%
2032 (forecast)
$1.13 Bn
+$168.0 Mn
+209.2%
2033 (forecast)
$1.33 Bn
+$197.5 Mn
+263.3%
2034 (forecast)
$1.56 Bn
+$232.0 Mn
+326.9%
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Novo Nordisk A/S, Eli Lilly and Company, Rhythm Pharmaceuticals, Kurbo (WW International), Teladoc Health (see all)
Active clinical trials
32 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Childhood Obesity Treatment Market Analysis Executive Summary
Childhood obesity treatment includes family programs, nutrition support, medicines and, for some teens, surgery to help children reach a healthier weight.
Key segments of the childhood Obesity Treatment market include treatment (Lifestyle and Behavioral Programs, Medication and Bariatric Surgery) and age (Children 6-11 and Adolescents 12-17).
Asia Pacific Childhood Obesity Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Childhood Obesity Treatment Market Dynamics
Market Growth Drivers
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the childhood Obesity Treatment market. Wider insurance coverage and more doctors trained in obesity care are adding to demand.
Opportunity
Oral formulations, combination therapies and use in heart, kidney and liver disease open new growth paths for the childhood Obesity Treatment market, especially in fast-growing emerging economies.
Market Restraints
High treatment prices, limited reimbursement, supply shortages and side effects that lead some patients to stop treatment hold back the childhood Obesity Treatment market. Long-term safety data and lifestyle support are still needed for many patients.
Competitive Landscape for Childhood Obesity Treatment Market in APAC
The childhood Obesity Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Childhood Obesity Treatment Market in APAC
Childhood Obesity Treatment in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9], Thai FDA (Thailand)[10], BPOM (Indonesia)[11], DRAP (Pakistan)[12], MFDS (South Korea)[13] and Drug Administration of Vietnam (Vietnam)[14]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[15], basic medical insurance (China)[16], the Hospital Authority (Hong Kong)[17], Ayushman Bharat PM-JAY (India)[18], public health insurance (Japan)[19], subsidised public care (Malaysia)[20], Pharmac (New Zealand)[21], PhilHealth (Philippines)[22], MediShield Life (Singapore)[23], the Universal Coverage Scheme (Thailand)[24], JKN (BPJS Kesehatan) (Indonesia)[25], out of pocket and Sehat Sahulat (Pakistan)[26], National Health Insurance (South Korea)[27] and social health insurance (Vietnam)[28]. ClinicalTrials.gov lists 32 studies on Childhood Obesity Treatment that are recruiting, active or about to start in APAC.[29]
[29]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for childhood Obesity Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Treatment
4.2 By Age
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Novo Nordisk
7.2 Eli Lilly and Company
7.3 Rhythm Pharmaceuticals
7.4 Kurbo (WW International)
7.5 Teladoc Health
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The childhood Obesity Treatment market can be segmented based on various criteria, including treatment, age and end user. Here's a breakdown of the market segmentation
What doctors and scientists are doing in Childhood Obesity Treatment right now, from free public sources.
Clinical trials
32 active trials in China, India, Japan, South Korea, Australia, Hong Kong, Philippines, Singapore, Thailand, Vietnam, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 18 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 21 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Childhood Obesity Treatment market in Asia Pacific?
Placeholder estimate: about $364.9 Mn in 2025, rising to about $1.56 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Childhood Obesity Treatment market in Asia Pacific growing?
Placeholder estimate: about 17.5% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Childhood Obesity Treatment market report cover?
The report splits the market by treatment (Lifestyle and Behavioral Programs, Medication, Bariatric Surgery), age (Children 6-11, Adolescents 12-17) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Childhood Obesity Treatment market?
Key players include Novo Nordisk A/S, Eli Lilly and Company, Rhythm Pharmaceuticals, Kurbo (WW International) and Teladoc Health.
What is driving the Childhood Obesity Treatment market?
Rising rates of obesity and type 2 diabetes, strong clinical results for new weight-loss medicines and growing acceptance of obesity as a chronic disease are driving the childhood Obesity Treatment market.
How many clinical trials on Childhood Obesity Treatment are running in Asia Pacific?
32 studies are recruiting, active or about to start in Asia Pacific, counted across the 18 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Childhood Obesity Treatment?
PubMed lists 54 papers on Childhood Obesity Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.